Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Asia
Pharma
China IIT, Daiichi Sankyo-AZ, Leo-Tanabe—Fierce Pharma Asia
China's alternative trial pathway draws scrutiny. AZ and Daiichi Sankyo's phase 3 lung cancer win. Tanabe's licensing deal. And more.
Donavyn Coffey
Aug 21, 2026 9:00am
Alfasigma gains drug, new territories with M&A play
Aug 12, 2026 11:23am
Alembic site hit with warning letter on patient consent concerns
Jul 21, 2026 11:40am
BioNTech to turn out the lights at Singapore vaccine facility
Apr 2, 2026 2:51pm
Novartis pledges nearly $480M to bolster China production, R&D
Mar 23, 2026 10:35am
EU-India trade pact to largely cull 11% tariff on European drugs
Jan 27, 2026 11:41am
